<\/p>\n
\ud83d\udca1 Rychl\u00e1 odpov\u011b\u010f<\/strong><\/p>\n Etibo<\/strong> je lapatinib 250 mg<\/strong>, , dual HER2\/EGFR tyrosine kinase inhibitor<\/strong> for advanced or metastatic HER2-positive breast cancer<\/strong>. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Etibo is a branded generic of lapatinib<\/strong> 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2)<\/strong> a EGFR (ErbB1)<\/strong>. Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.<\/p>\n Critical:<\/strong> Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol \u2014 typically after trastuzumab resistance develops.<\/p>\n Velmi \u010dast\u00e9:<\/strong> diarrhoea (60\u201380%), rash (40\u201360%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).<\/p>\n V\u00fdznamn\u00e9:<\/strong> hepatotoxicity<\/strong> (monitor LFTs), cardiotoxicity \/ reduced LVEF<\/strong> (5\u20136%), QT prolongation, interstitial lung disease (rare but serious).<\/p>\n Z\u00e1va\u017en\u00e9:<\/strong> severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.<\/p>\n Store at room temperature (15\u201330 \u00b0C), away from moisture. Keep in original packaging. Keep out of reach of children.<\/p>\n Advanced\/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.<\/p>\n Food increases lapatinib absorption 4\u20135\u00d7, making dosing unpredictable. Standard is consistent fasting \u2014 1 hour before or after food \u2014 at a fixed time each day.<\/p>\n Common, often grade 1\u20132; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.<\/p>\n About 5\u20136% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.<\/p>\n Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.<\/p>\n Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.<\/p>\n HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.<\/p>\n For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) have since largely supplanted it in first-world oncology \u2014 lapatinib remains important where newer agents are unavailable.<\/p>\n \u2695\ufe0f L\u00e9ka\u0159sk\u00e9 upozorn\u011bn\u00ed:<\/strong> Informace maj\u00ed vzd\u011bl\u00e1vac\u00ed charakter a nenahrazuj\u00ed l\u00e9ka\u0159skou pomoc. P\u0159ed zah\u00e1jen\u00edm, ukon\u010den\u00edm nebo zm\u011bnou jak\u00e9hokoli l\u00e9ku, zejm\u00e9na p\u0159i l\u00e9\u010db\u011b rakoviny, hormon\u00e1ln\u00ed terapii a p\u0159edepsan\u00fdch p\u0159\u00edpravc\u00edch, se pora\u010fte s l\u00e9ka\u0159em.<\/p>\n<\/div>\n <\/p>\n Dal\u0161\u00ed onkologick\u00e9 l\u00e9ky skladem vedle tohoto produktu:<\/p>\n \u2705 Targets cancer cells Etibo contains Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Etibo?<\/strong><\/h2>\n
Klinick\u00e9 pou\u017eit\u00ed<\/strong><\/h2>\n
\n
Jak u\u017e\u00edvat<\/strong><\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/strong><\/h2>\n
Who Should Not Take Etibo<\/strong><\/h2>\n
\n
Interakce s l\u00e9\u010divy<\/strong><\/h2>\n
\n
Skladov\u00e1n\u00ed<\/strong><\/h2>\n
\u010casto kladen\u00e9 dotazy<\/h2>\n
When is lapatinib used?<\/h3>\n
Why take on empty stomach?<\/h3>\n
How bad is the diarrhoea?<\/h3>\n
Will lapatinib damage my heart?<\/h3>\n
Can I take lapatinib with trastuzumab?<\/h3>\n
What about fertility?<\/h3>\n
Why is this in the Women's Health category?<\/h3>\n
Is lapatinib still first-line?<\/h3>\n
Souvisej\u00edc\u00ed produkty pro zdrav\u00ed \u017een<\/h3>\n
\n
Souvisej\u00edc\u00ed alternativy<\/h3>\n
\n
\n\u2705 Inhibits tumor growth
\n\u2705 Treats breast cancer
\n\u2705 Blocks HER2 receptors
\n\u2705 Zlep\u0161uje m\u00edru p\u0159e\u017eit\u00ed<\/p>\n